Singapore markets closed
Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,102.44 -712.12 (-1.83%) Hang Seng
17,936.12 -5.66 (-0.03%) FTSE 100
8,144.41 -2.45 (-0.03%) Bitcoin USD
65,353.97 -1,195.64 (-1.80%) CMC Crypto 200
1,374.70 -13.46 (-0.97%)
AMGN Mar 2025 220.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:20AM EDT. Market open.
| Previous close | 4.2000 |
| Open | 4.2000 |
| Bid | 3.6000 |
| Ask | 4.1000 |
| Strike | 220.00 |
| Expiry date | 2025-03-21 |
| Day's range | 4.2000 - 4.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
ZacksAmgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
ZacksAmgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
© 2024 Yahoo. All rights reserved.